Literature DB >> 18207125

Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls.

Kengo Hayashi1, Kyoko Ohno-Matsui, Satoshi Teramukai, Noriaki Shimada, Muka Moriyama, Wakako Hara, Takeshi Yoshida, Takashi Tokoro, Manabu Mochizuki.   

Abstract

PURPOSE: To examine the effects of photodynamic therapy (PDT) with verteporfin on subfoveal or juxtafoveal choroidal neovascularization (CNV) secondary to pathologic myopia in Japanese patients and to compare the visual outcomes of PDT-treated patients with that of age-matched and visual acuity-matched untreated controls.
DESIGN: Prospective, open-label, consecutive, interventional case series.
METHODS: We prospectively followed up 43 eyes of 42 consecutive patients with pathologic myopia (>6 diopters or axial length>26.5 mm) who received PDT for myopic CNV. In addition, the visual outcomes of these patients who were followed up for more than one year were compared with those of age- and initial visual acuity-matched untreated controls.
RESULTS: The average follow-up was 15.0+/-7.0 months. Patients received an average of 1.40+/-0.73 treatments during follow-up, and 30 eyes (69.8%) required only one treatment. The best-corrected visual acuity (BCVA) improved by more than two Snellen lines in seven eyes (16.3%), decreased in six eyes (14.0%), and remained stable in 30 eyes (69.7%). In three eyes with a juxtafoveal CNV, CNV could not be detected ophthalmoscopically or angiographically after PDT. Statistical analysis showed that the PDT-treated patients had significantly better visual acuity at one year after PDT than the age- and initial BCVA-matched untreated controls.
CONCLUSIONS: These results indicate that PDT was beneficial for maintaining vision in Japanese patients with myopic CNV. The visual outcome after PDT was better than the natural course of the disease as determined from untreated controls. The effect on chorioretinal atrophy around CNV should be investigated with a long-term study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18207125     DOI: 10.1016/j.ajo.2007.10.032

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  15 in total

1.  Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization.

Authors:  Riyo Uemoto; Houmei Nakasato-Sonn; Tatsukata Kawagoe; Meguro Akira; Eiichi Okada; Nobuhisa Mizuki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-22       Impact factor: 3.117

2.  Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization.

Authors:  C S Tan; M C Chew; T H Lim
Journal:  Eye (Lond)       Date:  2013-09-20       Impact factor: 3.775

3.  Intravitreal bevacizumab versus photodynamic therapy for myopic choroidal neovascularization in a North-African population.

Authors:  Leila El Matri; Fedra Kort; Ahmed Chebil; Rim Bouraoui; Ahlem Merdassi; Mejda Bouladi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-12       Impact factor: 3.117

4.  Epidemiology, treatment pattern and health care utilization of myopic choroidal neovascularization: a population based study.

Authors:  Ming-Chin Yang; Yen-Po Chen; Elise Chia-Hui Tan; Claudia Leteneux; Erin Chang; Carol Hy Chu; Chi-Chun Lai
Journal:  Jpn J Ophthalmol       Date:  2017-01-06       Impact factor: 2.447

5.  [Therapy of myopic choroidal neovascularization].

Authors:  B Voykov; F Ziemssen; K U Bartz-Schmidt
Journal:  Ophthalmologe       Date:  2012-08       Impact factor: 1.059

Review 6.  Genetic predictors of response to photodynamictherapy.

Authors:  Francesco Parmeggiani; Donato Gemmati; Ciro Costagliola; Francesco Semeraro; Paolo Perri; Sergio D'Angelo; Mario R Romano; Katia De Nadai; Adolfo Sebastiani; Carlo Incorvaia
Journal:  Mol Diagn Ther       Date:  2011-08-01       Impact factor: 4.074

7.  Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?

Authors:  Bogomil Voykov; Faik Gelisken; Werner Inhoffen; Michael Voelker; Karl Ulrich Bartz-Schmidt; Focke Ziemssen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-01-29       Impact factor: 3.117

8.  Factors affecting visual outcome of myopic choroidal neovascularization treated with verteporfin photodynamic therapy.

Authors:  Colin S Tan; Milton C Chew; Kai-Hung Lim; Tock-Han Lim
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

9.  Predictive factors for visual outcome to intravitreal bevacizumab in young Chinese patients with myopic choroidal neovascularization.

Authors:  Jane Zea-Chin Kuo; Frank Shih-Chang Ong; Ling Yeung; Wei-Chi Wu; Yen-Po Chen; Nan-Kai Wang; Chi-Chun Lai
Journal:  Retina       Date:  2011-10       Impact factor: 4.256

10.  Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy.

Authors:  Kengo Hayashi; Kyoko Ohno-Matsui; Noriaki Shimada; Muka Moriyama; Wakako Hara; Takeshi Yoshida; Takashi Tokoro; Manabu Mochizuki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-01-16       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.